Corcept Therapeutics Incorporated

While President Trump’s efforts to downsize the US Food and Drug Administration and plans to impose tariffs are currently spooking biopharma investors, some companies were able to defy the gloomy sent

Corcept Therapeutics’ cortisol modulator relacorilant improved progression-free survival (PFS) and overall survival (OS) in a Phase III trial in patients with platinum-resistant ovarian cancer, paving

With sales of Korlym (mifepristone), the leading Cushing’s disease drug, forecast to start falling next year, Corcept Therapeutics Incorporated needs a new money-spinner. Thanks to a hit in the piv

Citeline · Biopharma’s Must-Know 2023-4 Catalysts Podcast Time Stamps 00:07 Introduction 00:45 Cytokinetics, Inc. ’s aficamten 01.56 Corcept Therapeutics Incorporated ’s relacorilant 03:28 Sano